arrow
J

Jeffrey D. Rothstein

Johns Hopkins University
H指数:108
被引数:5.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Biobank-scale genetic characterization of Alzheimer’s disease and related dementias across diverse ancestries

生物银行规模下不同祖先来源的阿尔茨海默病及相关痴呆症的遗传表征

2025-08-140
OA
Corrigendum to “Comprehensive Proteomics Metadata and Integrative Web Portals Facilitate Sharing and Integration of LINCS Multiomics Data”

勘误:Comprehensive Proteomics Metadata and Integrative Web Portals Facilitate Sharing and Integration of LINCS Multiomics Data

2025-08-070
PRE
The Global Neurodegeneration Proteomics Consortium: biomarker and drug target discovery for common neurodegenerative diseases and aging

全球神经变性蛋白质组学联盟: 常见神经退行性疾病和衰老的生物标志物和药物靶点发现

2025-07-150
OAAI
Efficacy and Safety of Once Daily Dosing vs. Approved On/Off Dosing of Edaravone Oral Suspension Up to 48 Weeks in Patients With Amyotrophic Lateral Sclerosis (Study MT-1186-A02)

埃拉瓦酮口服混悬剂每日一次给药与批准的开关式给药在肌萎缩侧索硬化症患者中的疗效与安全性比较(48周,研究MT-1186-A02)

2025-06-060
OA
Large-scale differentiation of iPSC-derived motor neurons from ALS and control subjects
NEURON
IF15
2023-04-0128
OAAI
Poly(ADP-ribose) promotes toxicity of C9ORF72 arginine-rich dipeptide repeat proteins
2022-09-1411
OA
Identification of Therapeutic Targets for Amyotrophic Lateral Sclerosis Using PandaOmics - An AI-Enabled Biological Target Discovery Platform

使用人工智能生物靶标发现平台PandaOmics鉴定肌萎缩侧索硬化的治疗靶标

2022-06-2846
OAAI
Answer ALS, a large-scale resource for sporadic and familial ALS combining clinical and multi-omics data from induced pluripotent cell lines
2022-02-030
OAAI
A Phase 1 study of GDC-0134, a dual leucine zipper kinase inhibitor, in ALS
2022-01-1024
OA